Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study.

Biomarkers Coronary Angiography Coronary Artery Disease / diagnosis Humans Myocardial Infarction / diagnosis Prognosis Prospective Studies Receptors, Urokinase Plasminogen Activator
CAD SuPAR cardiac marker clinical-utility risk-stratification

Journal

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
ISSN: 1366-5804
Titre abrégé: Biomarkers
Pays: England
ID NLM: 9606000

Informations de publication

Date de publication:
May 2022
Historique:
pubmed: 4 2 2022
medline: 7 4 2022
entrez: 3 2 2022
Statut: ppublish

Résumé

Soluble urokinase plasminogen activator receptor (suPAR) is an emerging biomarker associated with anatomical CAD burden and cardiovascular outcomes including myocardial infarction (MI) and death. We aimed to validate previous findings of the prognostic value of suPAR and to evaluate its diagnostic potential for functional relevant CAD (fCAD). Consecutive patients with suspected fCAD were enrolled. Adjudication of fCAD was performed blinded to suPAR concentrations by myocardial perfusion single-photon emission tomography (MPI-SPECT) and coronary angiography. Prognostic outcome measures included all-cause death, cardiovascular death, and incident MI during 2-year follow-up. Among consecutive 968 patients, suPAR concentrations were higher in patients with fCAD compared to those without (3.45 SuPAR was an independent predictor of all-cause death, without diagnostic utility for fCAD. NCT01838148.

Sections du résumé

BACKGROUND BACKGROUND
Soluble urokinase plasminogen activator receptor (suPAR) is an emerging biomarker associated with anatomical CAD burden and cardiovascular outcomes including myocardial infarction (MI) and death. We aimed to validate previous findings of the prognostic value of suPAR and to evaluate its diagnostic potential for functional relevant CAD (fCAD).
METHODS METHODS
Consecutive patients with suspected fCAD were enrolled. Adjudication of fCAD was performed blinded to suPAR concentrations by myocardial perfusion single-photon emission tomography (MPI-SPECT) and coronary angiography. Prognostic outcome measures included all-cause death, cardiovascular death, and incident MI during 2-year follow-up.
RESULTS RESULTS
Among consecutive 968 patients, suPAR concentrations were higher in patients with fCAD compared to those without (3.45
CONCLUSIONS CONCLUSIONS
SuPAR was an independent predictor of all-cause death, without diagnostic utility for fCAD.
CLINICAL TRIAL REGISTRATION BACKGROUND
NCT01838148.

Identifiants

DOI: 10.1080/1354750X.2022.2038269 PMID: 35112976
pubmed: 35112976
doi: 10.1080/1354750X.2022.2038269
doi:

Substances chimiques

Biomarkers 0
Receptors, Urokinase Plasminogen Activator 0

Banques de données

ClinicalTrials.gov
['NCT01838148']

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-285

Auteurs

Joan Elias Walter (JE)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
Department of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Melissa Lee Fen Amrein (MLF)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
ORCID: 0000-0003-4522-0894

Ibrahim Schäfer (I)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Tobias Zimmermann (T)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Pedro Lopez-Ayala (P)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Jasper Boeddinghaus (J)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Raphael Twerenbold (R)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
University Heart & Vascular Center Hamburg, Hamburg, Germany.

Christian Puelacher (C)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Thomas Nestelberger (T)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
Vancouver General Hospital, University of British Columbia, Vancouver, Canada.

Desiree Wussler (D)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
Universitäts-Herzzentrum Bad Krozingen, Bad Krozingen, Germany.

Ursina Honegger (U)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Patrick Badertscher (P)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Jesper Eugen-Olsen (J)

Clinical Research Centre, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.

Luca Koechlin (L)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
Department of Cardiac Surgery, University Hospital Basel, University of Basel, Basel, Switzerland.

Gregor Fahrni (G)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Raban Jeger (R)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Christoph Kaiser (C)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Michael Zellweger (M)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Christian Mueller (C)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Soluble urokinase plasminogen activator...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic cardiovasculaire › Tests de la fonction cardiaque › Coronarographie › Soluble urokinase plasminogen activator...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Ischémie myocardique › Maladie coronarienne › Maladie des artères coronaires › Soluble urokinase plasminogen activator...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Soluble urokinase plasminogen activator...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Nécrose › Infarctus › Infarctus du myocarde › Soluble urokinase plasminogen activator...
questionsmedicales.fr › Diagnostic › Pronostic › Soluble urokinase plasminogen activator...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Soluble urokinase plasminogen activator...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs à l'activateur du plasminogène de type urokinase › Soluble urokinase plasminogen activator...